WHO Issues First Global Guidelines on Adult Type 1 Diabetes as European Medicines Agency Recommends Two Insulin Aspart Biosimilars
Marking World Diabetes Day 2026, WHO released its first clinical framework for adult type 1 diabetes across low-resource and humanitarian settings, one day after EMA's CHMP backed seven new medicines including two insulin biosimilars.
By 全球伯乐 News
Source compilation
On this page
Marking World Diabetes Day on November 14, the World Health Organization (WHO) issued its first global guidelines on the diagnosis and management of type 1 diabetes in adults, establishing evidence-based care standards tailored to all healthcare systems including low-resource, emergency, and humanitarian settings1. One day earlier in Amsterdam, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) published its November 9–12 meeting highlights, recommending seven new medicines for European Union marketing authorization — led in metabolic care by two new insulin aspart biosimilars2.

AI-generated editorial illustration: two completely unmarked clear borosilicate glass vials with silver caps, a smooth satin-aluminum injector pen form with a cobalt cap, and a matte white ceramic cold-chain block on flat pale travertine represent global insulin clinical access and biosimilar regulatory review, not a real clinical or agency photograph.
Addressing 9.5 Million Patients Worldwide with Tiered Insulin and Glucose Monitoring Standards
More than a century after the discovery of insulin, millions of adults dependent on daily replacement therapy still face severe affordability and supply disruptions. According to WHO's November 14 announcement, approximately 9.5 million people lived with type 1 diabetes worldwide in 2025, with 500,000 new cases diagnosed during the same year; across all forms of diabetes, global prevalence has more than quadrupled since 1990 to reach 830 million people in 2022, over 40 percent of whom remain undiagnosed1.
Noting that life-saving insulin remains out of reach in many disrupted health systems, Dr Søren Brostrøm, WHO Director of Noncommunicable Diseases and Mental Health, emphasized practical clinical adaptability. The guidelines recommend multiple daily insulin injections titrated to blood glucose readings and affirm manufactured human insulin as an appropriate, effective baseline therapy alongside other insulin formulations where needed1. For glycemic tracking, WHO pairs clinic-based multi-month average blood sugar testing with home finger-prick tests or skin-worn continuous glucose monitors (CGMs) — permitting urine glucose testing where blood assays are unavailable — to advance its 2030 target of universal access to affordable insulin and self-monitoring1.
EMA Committee Backs Seven New Medicines Including Two Rapid-Acting Insulin Aspart Biosimilars
Complementing WHO's clinical access push, European pharmaceutical regulators moved to expand competitive biologic supply and novel therapeutics. In its November 13 regulatory summary, EMA's CHMP adopted positive opinions on seven new medicines — three non-orphan innovator drugs, two biosimilars, and two generics — lifting its 2026 cumulative total to 79 positive new-medicine recommendations alongside 11 new therapeutic indication extensions (108 year-to-date)2.
Directly expanding diabetes treatment options, the committee endorsed two insulin aspart biosimilars — Garzulys (submitted by Sciencepharma Sp. z o.o.) and Donrafylix (submitted by Kuraci) — indicated for diabetes mellitus in adults, adolescents, and children aged one year and older2. Within the same session, CHMP recommended marketing authorizations for Aumseqa (aumolertinib) and Zybrivo (sintilimab) in non-small cell lung cancer, Baxfendy (baxdrostat) for insufficiently controlled hypertension in adults, and generic formulations Fondaparinux sodium Evumed for thromboembolic events and Ruxolitinib Krka for myelofibrosis, polycythaemia vera, and graft-versus-host disease2.
Cross-Regional Regulatory Collaboration and Metabolic Pharmacovigilance Guidance
Beyond initial approvals, CHMP recommended extending Roche's Gazyvaro (obinutuzumab) to adults with moderate-to-severe active systemic lupus erythematosus to curb disease flares and corticosteroid reliance, extending Isturisa (osilodrostat) to children aged six and older with endogenous Cushing's syndrome, and broadening indications for nine additional EU-authorized medicines including the diabetes therapy Steglatro (ertugliflozin)2. Under the EU-Medicines for all (EU-M4All) pathway — evaluated jointly with WHO experts and national regulators from Kenya, South Africa, and Zambia — the committee also backed a three-month 100 mg Dapivirine Vaginal Ring to reduce HIV-1 infection risk outside the EU2.
At the same meeting, CHMP adopted a direct healthcare professional communication (DHPC) for Mounjaro (tirzepatide) in type 2 diabetes and weight management, advising women using oral contraceptives to add barrier contraception for four weeks after starting therapy and after each dose escalation, or switch to non-oral methods2. Together, WHO's resource-stratified adult type 1 diabetes protocols and EMA's biosimilar insulin clearances highlight converging international efforts to pair standardized frontline care with broader, more affordable medicine supply12.


